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O R I G I N A L A R T I C L E
Extracorporeal photopheresis for graft-versus-host disease:
the role of patient, transplant, and classification criteria and
hematologic values on outcome—results from a large
single-center study
Massimo Berger,1 Roberto Albiani,2 Bruno Sini,2 and Franca Fagioli1
BACKGROUND: Extracorporeal photopheresis (ECP)
has been shown as active therapy for graft-versus-host
disease (GVHD).
STUDY DESIGN AND METHODS: The aim was to
ascertain the role of ECP in 71 patients with steroid-
refractory or -dependent acute and chronic GVHD
(aGVHD and cGVHD) with special focus on hemato-
logic variables and GVHD staging classification. A total
of 34 patients were treated for aGVHD and 37 for
cGVHD.
RESULTS: The overall response rate (ORR) for
aGVHD was 65% and the complete aGVHD-free sur-
vival was 50% (95% confidence interval [CI], 36%-
70%). The ORR for cGVHD response was 81% while
the complete cGVHD-free survival was 50% (95% CI,
34%-73%). The aGVHD-free survival was associated
with aGVHD grading (Grade II 81%, Grade III 33%, and
Grade IV 0%, p ≤ 0.00) and the absence of visceral
involvement (77% vs. 33%, p = 0.03). The cGVHD-free
survival was associated with the female sex (67% vs.
25%, p = 0.01) and with the limited form according to
the Seattle classification (67% vs. 20%, p = 0.003). No
role for hematologic values or apheresis cell count was
found, except for the cGVHD ORR (p = 0.037).
Transplant-related mortality and overall survival were
associated with ECP response 0% versus 54%
(p = 0.0001) and 77% versus 45% (p = 0.03) for
aGVHD patients and 7% versus 14% (p = 0.02) and
73% versus 20% (p = 0.0003) for cGVHD patients,
respectively.
CONCLUSIONS: While confirming a higher probability
of GVHD responses for early GVHD, our study shows
no role of hematologic values or apheresis cell count on
GVHD response.
G
raft-versus-host disease (GVHD) remains the
most frequent complication after allogeneic
hematopoietic stem cell transplantation
(HSCT).1 First described as a “secondary
disease” in mice,2 the syndrome was shown to be triggered
by immunocompetent donor cells.3,4 Despite improve-
ments in posttransplant immunosuppression, up to 30%
of HLA-identical graft recipients and up to 90% of recipi-
ents of unrelated donor graft still develop significant acute
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GVHD (aGVHD). Prednisone has been shown to be effec-
tive as the first-line therapy in the treatment of established
aGVHD, resulting in complete response (CR) rates of 25%
to 54%.5,6 However, patients not responding to steroids are
at a high risk of death.7,8 Furthermore, despite better
donor selection, GVHD prophylaxis, and treatment,
chronic GVHD (cGVHD) affects 50% of long-term trans-
plant survivors and is lethal in 20% to 40% of affected
patients.9 Primary therapy for extensive cGVHD usually
includes steroids and calcineurin inhibitors,10-18 but the
probability of cGVHD response is highly variable.19-23
Extracorporeal photopheresis
(ECP) was introduced nearly 30 years
ago to treat cutaneous T-cell lymphoma
and autoimmune diseases, such as
scleroderma. This procedure has proved
effective in the treatment of acute lung,
heart, and kidney allograft rejection and
in the past 15 years for the treatment of
aGVHD and cGVHD, gaining levels of
evidence of C for skin aGVHD, B for skin
cGVHD, and C for nonskin aGVHD and
cGVHD.24 Although the mechanisms
of ECP are not fully understood, recent
evidence suggests how the T-, B-, and
dendritic cells compartment may be
regulated by ECP.25-27 In this study we
report our clinical experience on 71
consecutive patients with GVHD treated
with ECP.
MATERIALS AND METHODS
Design of the study and
ECP procedures
Seventy-one patients with steroid-
resistant or -dependent aGVHD (n = 34)
or cGVHD (n = 37, Table 1) were
enrolled for ECP treatment in our center
from October 2001 to September 2013.
Inclusion criteria were as follows: 1)
diagnosis of aGVHD or cGVHD based
on clinical and laboratory documenta-
tion, 2) previous therapy with steroids
for at least 7 days plus calcineurin
inhibitors for aGVHD or other immuno-
suppressive treatments but not started
14 days before ECP, and 3) no previous
treatment with either antithymocyte
globulin or monoclonal antibodies
within 1 month before starting ECP.
Exclusion criteria were as follows: 1)
previous ECP treatment, 2) hemody-
namic instability, 3) inadequate compli-
ance to attend the procedures, and 4) no previous
corticosteroid treatment.
ECP was performed on both an outpatient and an
inpatient basis. Patients were treated with ECP on 2 con-
secutive days at weekly intervals for the first month,
every 2 weeks during the second and third months, and
then at monthly intervals for an additional 3 months.
Briefly, patients with aGVHD were excluded from the
ECP protocol if they had: 1) completed their planned
22 procedures or 2) had aGVHD progression under
ECP.
TABLE 1. aGVHD and cGVHD patient characteristics*
Patient characteristics aGVHD (%) cGVHD (%) p value†
Number 34 37 NS
Male/female 16/18 28/9 0.008
Age at HSCT (years), median (range) 12 (2-49) 26 (5-65) 0.001
Disease
AML 2 (6) 10 (27) NS
ALL 13 (38) 11 (30)
CML 6 (18) 4 (11)
MDS/MPD 2 (6) 2 (5)
Lymphoma 3 (9) 4 (11)
Multiple myeloma 0 2 (5)
Solid tumor 2 (6) 1 (3)
Nonmalignant 6 (18) 3 (8)
ABO compatibility
Major incompatibility 13 (38) 11 (30) NS
Minor incompatibility 7 (20) 11 (30)
Identical 14 (41) 15 (40)
CMV serology
D–/R– 7 (20) 4 (11) NS
Other 27 (79) 33 (89)
Disease status at HSCT
Early 10 (29) 12 (32) NS
Advanced 24 (70) 25 (67)
Donor type
MFD 8 (23) 25 (67) 0.0008
MUD 26 (76) 12 (32)
Sex mismatch
Female donor/male recipient 7 (20) 18 (49) 0.01
Other combination 27 (79) 19 (51)
Conditioning regimen
Myeloablative 26 (76) 25 (67) NS
Nonmyeloablative 8 (23) 12 (32)
GVHD prophylaxis
With serotherapy 25 (73) 9 (24) 0.0002
Without serotherapy 9 (26) 28 (76)
Stem cell source
BM 22 (65) 17 (46) 0.03
PB 9 (26) 20 (54)
CB 3 (9) 0
* Data are reported as number (%) unless otherwise specified.
† The p value was calculated by the chi-square tests or the Fisher exact test.
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic
myeloid leukemia; D– = donor CMV serologically negative; MDS = myelodysplastic
syndrome; MPD = myeloproliferative disorders; R– = recipient CMV serologically negative.
Early disease—CR1 for AML and ALL, CP1 for CML, or other myeloproliferative disor-
ders. MDSs were considered as early or advanced according to blast counts in the
peripheral blood, CR2 for lymphomas, or no evidence of disease for solid tumors and all
nonmalignant diseases. Advanced diseases were considered any other disease status at
HSCT and patients receiving second HSCT. D = donor; MFD = matched family donor;
MUD = matched unrelated donor; R = recipient. Myeloablative—any conditioning regimen
containing total body irradiation above 9.9 Gy, busulfan above 14 mg/kg, or thiotepa
above 10 mg/kg. BM = bone marrow; CB = cord blood; PB = peripheral blood.
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Any concomitant immunosuppressive medication
was initially maintained and then modified or discontin-
ued according to the clinical response.
Depending on the characteristics of the patient (pedi-
atric or adult), our center has two different systems for
ECP. We use a photopheresis instrument (UVAR, Therakos,
Exton, PA) for adults or for patients weighing more than
40 kg because it requires a considerable extracorporeal
circulation. After 240 mL of mononuclear cells was col-
lected, 300 mL of plasma was added to 200 mL of normal
saline and 8-methoxypsoralen (100 mg, Gerot Pharma-
ceutical, Vienna, Austria) in aqueous solution and, finally,
the buffy coat and plasma were passed in as a thin film
through a disposable plastic device, exposed to UVA light
(2 J/cm2) for 90 minutes, and then returned to the
patients. For pediatric patients (weighing under 40 kg)
lymphocytapheresis procedures were performed by
means of a continuous-flow cell separator (Fresenius
COM.TECH [before this cell separator, for some patients,
we used the CS3000 cell separator, Fenwal, Baxter,
Deerfield, IL]) and then, via a closed system, cells were
transferred to a 3000-mL thin plastic bag. Thereafter,
100 mg of 8-methoxypsoralen (Gerot Pharmaceutical)
was added to a final concentration of 200 ng/mL. Before
2012 the product was photoinactivated (2 J/cm2) with a
dermatologic-use device (PUVA Combi light, PCL Division
Overkade, Hands Unit, Leuven, Belgium) and after 2012
by another UVA device (Macogenic G2, Macopharma,
Tourcoing, France). Considering that in patients weighing
less than 40 kg the Therakos device could not be used due
to the high extracorporeal circulation, the company gave
us the systems to bypass the collection phase and allowed
us to use only the phase of photoinactivation. At least two
blood volumes were processed.
During the ECP procedures all patients were moni-
tored for blood pressure, heart rate, and body tempera-
ture. Full blood count, liver and kidney function tests, and
coagulation variables were obtained before and after each
procedure. An aliquot of each collection before reinfusion
was analyzed for the cell count.
This study was approved by the local institute review
board or ethics committee; all patients or parents or legal
guardians gave their consent for ECP procedures. A spe-
cific informed consent was given for adolescents.
aGVHD patients
A total of 34 patients underwent ECP for steroid-refractory
aGVHD from June 2001 to September 2013. A median of 11
ECP procedures per patient were performed (range, 8-25).
The median follow-up for surviving patients was 4 years
(range, 2 months-12 years), while it was 7 months for
deceased patients (range, 35 days-11 months). The
median (range) patient weight was 39 (10-98) kg and
aGVHD was graded II for 16 patients (47%), III for 12
(35%), and IV for six patients (18%). The median (range)
white blood cell (WBC) count at ECP start was 5.6 × 109
(1.2 × 109-18 × 109)/L and the first 80 ECP procedures gave
a median (range) of 4 × 108 (1 × 108-13 × 108) total nucle-
ated cells (TNCs)/kg. The median (range) patient age at
HSCT was 12 (2-42) years, while for donors it was 28 (0-49)
years. The median (range) age at ECP start was 12 (2-51)
years. The median (range) interval between HSCT and
ECP start was 38 (15-97) days (details of aGVHD patients
and ECP are outlined in Tables 1 and 2).
cGVHD patients
A total of 37 patients underwent ECP for cGVHD from
April 2001 to March 2013. A median of 20 ECP procedures
per patient was performed (range, 8-77). The median
(range) follow-up for surviving patients was 4 years (1
month-12 years), while it was 2 years for deceased patients
(30 days-4 years). The median (range) age at HSCT was 22
(4-64) years, while for donors it was 35 (5-63) years. The
median (range) age at ECP start was 26 (5-64) years. The
median (range) patient weight at ECP start was 55 (14-
100) kg and the median (range) WBC count at ECP start
was 6.5 × 109 (2.1 × 109-17.9 × 109)/L, the first eight ECP
procedures gave a total of 5.9 × 108 (0.07 × 108-65.3 × 108)
TNCs/kg. The median (range) interval between HSCT and
ECP start was 193 (10-5681) days.
cGVHD classification
For patients diagnosed before 2005 for National Institutes
of Health (NIH) classification and before 2011 for Center
for Bone Marrow Transplant Research (CIBMTR) classifi-
cation, the patients’ medical records were retrospectively
reviewed. In brief, 12 patients were diagnosed with limited
cGVHD and 25 with extensive cGVHD according to the
Seattle classification; 14 patients were classified as mild,
18 with moderate, and five with severe cGVHD according
to the NIH classification; and finally nine patients were
scored as Risk Group 1 (RG1), 26 patients as RG2, and two
patients as ≥RG3 according to the CIBMTR classification
(details of cGVHD patients and ECP are outlined in
Tables 1 and 3). To retrospectively assess the NIH or
CIBMTR classification, all medical records and histologic
and radiologic tests were critically reviewed by two skilled
BMT attending physicians (MB and FF).
Criteria for defining response to ECP
Response to therapy was assessed clinically at weekly
intervals. The clinically relevant time points for response
were 1 month for aGVHD patients and 3 months for
cGVHD. The criteria for defining responses for aGVHD
were as previously reported,28 briefly:
1. CR—overall GVHD Grade 0 to I;
2. Partial response (PR)—more than 50% of organ
involvement (skin, gut, and liver);
3. Minor response—tapering of immunosuppressive
agents with stable GVHD;
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4. Stable disease—less than 50% response of organ
involvement (skin, gut, and liver); or
5. Progressive disease (PD)—worsening of organ
involvement or new signs and/or symptoms of
GVHD. Patients with a CR or PR in one organ and a
simultaneous PD in another were diagnosed as pro-
gression of aGVHD.
Criteria for defining responses for cGVHD were as
follows:
1. CR—complete regression of any cGVHD
manifestation.
2. PR—more than 50% in terms of organ involvement. In
this case, due to the complexity inherent to the
assessment of response in each organ, we defined PR
as follows: skin GVHD, for lichenoid rashes a
minimum 50% reduction in the body surface area
involved; for sclerodermatous involvement, any
improvement in the skin score or range of motion,
with an improvement of Zubrod/Eastern Cooperative
Oncology Group performance status of 1;29 ocular
GVHD, a subjective improvement and a reduction in
the frequency of artificial tears administration by
50%, or an improvement in the Schirmer test for one
or both eyes; oral GVHD, a 50% improvement in the
mucosal area involved with lichenoid and/or ulcer-
ative changes; gastrointestinal and liver, 50%
decrease in the volume of diarrhea, bilirubin, alkaline
phosphatase, or γ-glutamyltransferase if abnormal at
ECP start; bronchiolitis obliterans, sustained
improvement in pulmonary function test (1-sec
forced expiratory value) assessed by monthly testing
and/or the ability to taper steroids by 50% with no
deterioration of pulmonary functions.
3. Minor response—tapering of immunosuppressive
agents with stable GVHD.
4. Stable disease—less than 50% of cGVHD organ
involvement.
5. PD—worsening of organ involvement or new signs
and/or symptoms of GVHD. Patients with a CR or PR
in one organ and a simultaneous PD in another were
diagnosed as progression of cGVHD.30
Endpoints, definitions, and statistical analysis
The primary endpoint of this study was to assess the long-
term effectiveness of ECP on steroid-resistant or
-dependent GVHD. The secondary endpoints were:
1. The overall response rate (ORR; CR+PR) for aGVHD
and cGVHD patients.
2. The role of TNCs and lymphocytes collected during
the first eight ECP procedures on response. The ECP
TABLE 2. Details of aGVHD patients and ECP characteristics*
GVHD diagnosis (days) 18 (9-92)
Age at GVHD diagnosis (years) 12 (2-49)
Patient weight (kg) 39 (10-98)
Karnofsky/Landsky score at GVHD (%) 80 (60-100)
Maximum GVHD staging
Grade II 16 (47)
Grade III 12 (35)
Grade IV 6 (18)
GVHD 0-I GVHD II GVHD III GVHD III-IV
Skin GVHD 2 2 27 5
Liver GVHD 27 2 2 5
Gut GVHD 23 1 6 6
Number of ECP procedures 11 (8-25)
At ECP start
WBC count (×109/L) 5.6 (1.2-18)
Neutrophil count (×109/L) 4.4 (0.6-13.8)
Lymphocyte count (×109/L) 0.7 (0.1-2.6)
Monocyte count (×109/L) 0.5 (0-3.9)
Hemoglobin (g/dL) 10.8 (8.6-15.3)
Hematocrit (%) 30.2 (25-3-44.4)
PLT count (×109/L) 74 (31-312)
ECP Procedures 1-8, harvested cells/kg (×108)
WBCs 4 (1-13)
Lymphocytes 1.5 (0.1-9.3)
ECP Procedures 9-16, harvested cells/kg (×108)
WBCs 3.3 (0.2-9.5)
Lymphocytes 1.8 (0.1-8)
ECP Procedures 17-22, harvested cells/kg (×108)
WBCs 2.5 (0.9-5.1)
Lymphocytes 1.5 (0.5-4.9)
* Data are reported as median (range) or number (%).
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harvested cells/kg count was computed by the addi-
tion of harvested TNCs or lymphocytes of ECP from
one to eight (that was chosen because all patients
completed the first month of treatment);
3. The correlation of WBCs, lymphocytes, monocytes,
and platelet (PLTs) before ECP start on response;
4. The cGVHD response according to the Seattle,19
NIH,20 and CIBMTR criteria;21
5. Transplant-related mortality (TRM), relapse inci-
dence (RI), and overall survival (OS) for both aGVHD
and cGVHD groups. For patients treated before 2005,
all the medical records were reviewed to stratify
patients according to the NIH criteria and for those
who were treated before 2011 the same approach was
used for the CIBMTR criteria. To assess retrospec-
tively the NIH or CIBMTR classification, all medical
records and histologic and radiologic tests were criti-
cally reviewed by two skilled BMT attending physi-
cians (MB and FF).
Steroid-resistant aGVHD was defined as progressive
aGVHD after at least 3 days of methylprednisolone (MP;
2 mg/kg/day) or if unimproving Grades III and IV aGVHD
persisted after at least 7 days of MP (2 mg/kg/day). Pro-
gression was defined as a change in one organ (skin, gut,
or liver) leading to an increase by at least one Glucksberg’s
stage of aGVHD. Unimproving aGVHD was defined as the
absence of a difference in any involved organ sufficient to
meet minimal criteria for improvement or deterioration.
cGVHD was considered refractory or resistant to
therapy if: 1) patients had stable disease (i.e., no response)
after 1 month of treatment, 2) no more than a PR occurred
after 2 months of treatment, or 3) PD occurred after 2
weeks of initiation of steroid treatment or during MP
taper.31 Steroid-dependent cGVHD was defined as the
patient’s need for prednisone or MP of at least 1 mg/kg.
Patient-, disease-, and transplantation-related vari-
ables are expressed as medians and ranges, or as percent-
ages, as appropriate. The following patient- or transplant-
related variables were analyzed for their potential impact
on GVHD response and GVHD-free survival: age, sex, stem
cell source, sex mismatch, donor type, first-line therapy
for aGVHD; and age, sex, stem cell source, sex mismatch,
donor type, cGVHD type of onset, Seattle criteria, NIH
criteria, and CIBMTR criteria for cGVHD. For aGVHD and
cGVHD groups, the TNCs/kg and lymphocytes/kg during
the first eight ECP procedures together the WBCs, lym-
phocytes, monocytes, and PLT count before ECP start
were also evaluated for GVHD response and GVHD-free
survival.
For the analysis of the ORR the chi-square test or the
Fisher exact test were used. For the statistical analyses the
continuous variables were categorized as follows: each
variable was first divided into four categories at the 25th,
50th, and 75th percentiles. If the relative event rates (the
ratio of the observed number of events to the expected
number of events in the category) in two or more adjacent
categories (and the median time to events) did not differ,
those categories were grouped. If no clear pattern was
observed for the primary outcomes, the median was taken
as the cutoff point.
aGVHD- or cGVHD-free survival was the probability
of being alive with continuous complete GVHD resolution
from ECP start. The competitive events for calculating
GVHD-free survival were both the TRM and the RI. TRM
was defined as the probability of dying without a previous
occurrence of a relapse, which was its competing event.
The method of TRM estimation was the cumulative
TABLE 3. Details of cGVHD patients and
ECP characteristics*
Day of cGVHD diagnosis 166 (100-1023)
Age of cGVHD diagnosis (years) 22 (5-64)
Patient weight (kg) 55 (14-100)
Onset























Number of ECP procedures per patient 20 (8-77)
Day of ECP start 193 (10-5681)
At ECP start
WBCs (×109/L) 6.5 (2.1-17.9)
Neutrophils (×109/L) 4.1 (0.3-11.5)
Lymphocytes (×109/L) 1.7 (0.2-7.8)
Monocytes (×109/L) 0.8 (0.1-2)
Hemoglobin (g/dL) 13 (8.6-16.3)
Hematocrit (%) 36 (26.2-45.8)
PLTs (×109/L) 231 (21-438)
ECP Procedures 1-8, harvested cells/kg (×108)
WBCs 5.9 (0.07-65.3)
Lymphocytes 3.8 (0.03-49)
ECP Procedures 9-16, harvested cells/kg (×108)
WBCs 4.9 (1.3-19.2)
Lymphocytes 2.1 (0.6-14.8)
ECP Procedures 17-22, harvested cells/kg (×108)
WBCs 4.7 (0.58-49)
Lymphocytes 1.9 (0.28-32)
* Data are reported as median (range) or number (%).
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incidence curve, the p value was calculated by the Gray
test.32 RI was defined as the probability of having had a
relapse before death or the last follow-up. In case of non-
malignant disease, the primary or secondary graft failures
were categorized as relapse. Death without experiencing a
relapse was the competing event. The RI method of esti-
mation was the cumulative incidence curve; the p value
was calculated by the Gray test. OS was calculated as the
probability of survival irrespective of disease state at any
time. OS was calculated by the Kaplan-Meier statistics,33
and the p value was calculated by the log-rank test.34
All variables having a p value below 0.20 in univariate
analyses were included in a multivariate analysis by the
Cox regression model; the proportional subdistribution
hazard regression model was used to perform multivariate
analyses of GVHD-free survival, RI, and TRM.35 Statistical
analysis was performed using computer software (SPSS,
SPSS, Inc., Chicago, IL) to calculate the OS, while the
cumulative incidence curves were calculated by another
computer program (NCSS for Windows, NCSS, LLC,
Kaysville, UT). The p values for both univariate and mul-
tivariate analyses were computed with a statistical com-
puting program (R packages software, http://www.r-




Among the aGVHD patients the ORR was 65%. In the uni-
variate analysis the lower GVHD grading (p = 0.0005) and
the steroid alone as the previous therapy (p = 0.01) were
significantly associated with better probabilities of
response. In particular, the Grade II aGVHD had 87% of
ORR, and Grade III had 67%, while no patients with
aGVHD Grade IV responded to ECP. The collected TNCs or
the hematologic values before ECP were not associated
with aGVHD response. Notably, the donor type and the
stem cell source had no relevance on aGVHD response.
Patients with higher WBC had a statistically significant
higher TNC yield (p = 0.02), but this did not translate in
higher ORR (Table 4).
The median interval between ECP start and the best
response day was 47 days. Steroids were tapered in 25
patients (67%) and the median number of days of steroid
tapering was 29 days. No toxicity greater than 1 has been
reported in accordance with the Common Toxicity Criteria
Adverse Event criteria available over the years.
aGVHD-free survival
For all patients the aGVHD-free survival was 50% (95%
confidence interval [CI], 34%-73%; Fig. 1). In univariate
analysis the aGVHD grades were significantly associated
with different outcomes: Grade II had 81% (95% CI, 64%-
100%), Grade III aGVHD had 33% (95% CI, 15%-74%), and
Grade IV aGVHD had 0% (p < 0.0008). When we consid-
ered the collected TNCs or lymphocytes or the hemato-
logic values before ECP the probability of aGVHD-free
survival did not differ even when the patients were strati-
fied according to quartiles (data not reported). The multi-
variate analysis showed how only the GVHD grade was the
sole independent factor with relative risk (RR) of 3.37 (95%
CI, 2.44-5.07, p = 0.0015).
TRM, RI, and OS
The 10-year TRM was 16% (95% CI, 8%-35%). The TRM
was 0% for responders versus 54% for nonresponders
(95% CI, 32%-93%, p = 0.0001). The 10-year cumulative
incidence of relapse was 17% (95% CI, 8%-35%). The RI
was 27% (95% CI, 14%-54%) for responders and 0% for
nonresponders (p = NS). The 10-year OS was 51% (95%
CI, 25%-78%). The OS was 77% (95% CI, 58%-94%)
for responders and 45% (95% CI, 16%-75%) for
nonresponders (p = 0.03; Table 5). The main cause of
death was aGVHD (six of 11, 54%) while the disease pro-
gression was the cause of death (five of 11, 45%) for the
other patients.
cGVHD response
The ORR for cGVHD patients was 81%. Bone marrow as
the stem cell source (p = 0.02), the female sex (p = 0.05),
the collected lymphocytes/kg during the first eight ECP
procedures (p = 0.037), the unrelated donor (p = 0.006)
and the limited form according to the Seattle criteria
(p = 0.027) were significantly associated with higher
response rates (Table 4). No effect of TNC/kg doses or
hematologic values at baseline were observed. Finally, the
probability of higher TNC collection did not differ accord-
ing to WBCs at baseline (p = NS). A total of 31 patients
(84%) could taper steroids and the median interval from
ECP start to steroid tapering was 59 days. Five patients
continued ECP therapy beyond 22 procedures as the sole
cGVHD treatment. No toxicity greater than 1 has been
reported in accordance with the Common Toxicity Criteria
Adverse Event criteria available over the years.
cGVHD-free survival
The 10-year cGVHD-free survival rate was 50% (95% CI,
34%-73%; Fig. 2) and the median lapse from ECP start to
best response was 393 days (14-1464 days). As reported in
Table 6, two variables had a significant deleterious effect
on cGVHD-free survival: the male sex (25% [95% CI, 13%-
47%] vs. 67% [95% CI, 42%-100%]; p = 0.01) and the exten-
sive type according to the Seattle criteria (20% [95% CI,
9%-44%] vs. 67% [95% CI, 45%-91%]; p = 0.003). When we
focused on collected TNCs or lymphocytes, we found
BERGER ET AL.
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TABLE 4. ORR for patients with aGVHD or cGVHD
Variables
aGVHD response (n = 34) cGVHD response (n = 37)
Number (%) p value* Number (%) p value*
Age at ECP
≥Median 8/16 (50) 0.15 12/18 (67) 0.12
<Median 14/18 (78) 17/19 (89)
Sex
Male 10/16 (62) 1 14/28 (50) 0.05
Female 12/18 (67) 8/9 (89)
Stem cell source
BM 15/22 (68) 0.22 16/17 (94) 0.02
PB 4/9 (44) 12/20 (60)
CB 3/3 (100) NA
Sex mismatch
Female > male 5/7 (71) 1 14/18 (78) 0.65
Other 17/27 (63) 15/17 (88)
GVHD grade
II 14/16 (87) 0.0005 NA
III 8/12 (67) NA
IV 0/6 (0) NA
Donor type
MFD 6/8 (75) 0.68 13/26 (50) 0.006
MUD 16/26 (61) 11/11 (100)
First-line therapy
Steroids 22/30 (73) 0.01 NA
Steroids plus other 0/4 (0) NA
Visceral aGVHD
Yes 11/13 (85) 0.07 NA
No 11/21 (52) NA
cGVHD onset type
De novo NA 10/12 (83) 1
Quiescent NA 11/14 (78)
Progressive NA 9/11 (82)
Seattle criteria
Limited NA 11/12 (92) 0.027
Extensive NA 13/26 (50)
NIH criteria
Mild NA 12/15 (80) 0.56
Moderate NA 13/18 (72)
Severe NA 5/5 (100)
CIBMTR criteria
RG1 NA 8/9 (89) 0.12
RG2 NA 14/26 (54)
RG3 NA 1/2 (50)
TNCs/kg
≥Median 10/14 (71) 0.44 14/16 (87) 0.21
<Median 7/13 (54) 10/15 (67)
Lymphocytes/kg
≥Median 10/13 (77) 0.23 15/16 (94) 0.037
<Median 7/14 (50) 9/15 (60)
WBCs before ECP
≥Median 11/18 (61) 0.72 17/19 (89) 0.12
<Median 11/16 (69) 12/18 (67)
Lymphocytes before ECP
≥Median 12/18 (67) 1 15/19 (79) 1
<Median 10/16 (62) 14/18 (78)
Monocytes before ECP
≥Median 12/20 (60) 0.71 15/17 (88) 0.22
<Median 10/14 (71) 12/16 (75)
PLTs before ECP
≥Median 12/19 (63) 1 15/19 (79) 1
<Median 10/15 (67) 14/18 (78)
* The p value was calculated by the chi-square test or the Fisher exact test.
BM = bone marrow; CB = cord blood; female > male = female donor for a male recipient; MFD = matched family donor; MUD = matched unre-
lated donor; PB = peripheral blood.
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no differences of cGVHD-free survival among the groups,
even when the patients were stratified according to
quartiles (data not reported). Interestingly, when we
compare the cGVHD-free survival for male patients
having a female donor to other combinations, no signifi-
cant differences were observed.
The sex, the extensive form according to Seattle crite-
ria, and the moderate and severe forms according to NIH
criteria were independent poor prognostic factors in mul-
tivariate analyses: the male sex had a RR of 2.03 (95% CI,
1.78-2.2; p = 0.01), the Seattle extensive form had a RR of
12.31 (95% CI, 7.88-16.6; p < 0.00), the NIH moderate form
had a RR of 12.51 (95% CI, 7.22-17.8; p < 0.00), and the NIH
severe form had a RR of 10.89 (95% CI, 4.4-16.1; p < 0.00)
for poorer cGVHD-free survival.
TRM, RI, and OS
The 10-year TRM for all patients was 10% (95% CI,
4%-26%). The TRMs were 7% (95% CI, 2%-25%) and 14%
(95% CI, 2%-89%) for responders and nonresponders,
respectively (p = 0.02). The cumulative incidence of RI for
the whole patient population was 24% (95% CI, 13%-42%).
The RI was 20% (95% CI, 10%-41%) and 43% (95% CI,
18%-100%) for responders and nonresponders (p = NS),
respectively. The OS rates were 73% (95% CI, 54%-92%)
and 20% (95% CI, 0%-55%) for responders and
nonresponders, respectively (p = 0.0002). The main cause
of death was disease progression (eight of 10, 80%), and
for the others the GVHD (one of 10, 10%) and bacterial
sepsis (one of 10, 10%) were the causes of death.
DISCUSSION
Steroids, the first line of GVHD treatment, fail in approxi-
mately 50% of patients and are broadly immunosuppres-
sive, increasing the risk of relapse, infections, and other
toxicities.7,18 Strategies to mitigate GVHD while preserving
immune functions are important to improve outcomes
after HSCT.36,37 ECP has proven efficacy in treating both
aGVHD and cGVHD, even in those patients who are
refractory to conventional immunosuppressive therapy,
with very few side effects reported.38 The mechanism of
action of ECP in GVHD is not fully understood. It has been
proposed that ECP modulates host effector cells, includ-
ing CD8+ T-lymphocytes, natural killer cells, and circulat-
ing antigen-presenting cells, leading to an attenuation of
host antigen-presenting activity and thus to the develop-
ment of tolerance.39-43 In particular, an elegant study
revealed that ECP induces a high percentage of processed
monocytes to enter the antigen-presenting dendritic cell
TABLE 5. Outcome of patients treated with ECP for aGVHD and cGVHD*
Outcome
aGVHD patients cGVHD patients
Responders Nonresponders p value Responders Nonresponders p value
TRM 0 54 (32-93) 0.0001 7 (2-25) 14 (2-89) 0.02
RI 27 (14-54) 0 0.07 20 (10-41) 43 (18-100) 0.14
OS 77 (58-94) 45 (16-75) 0.03 73 (54-92) 20 (0-55) 0.0002
* Data are reported as percent (95% CI).
Fig. 1. aGVHD-free survival, TRM, and RI for patients who
underwent ECP for aGVHD.
Fig. 2. cGVHD-free survival, TRM, and RI for patients who
underwent ECP for cGVHD.
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TABLE 6. aGVHD- and cGVHD-free survival
Variables
aGVHD-free survival (n = 34) cGVHD-free survival (n = 37)
Percent (95% CI) p value* Percent (95% CI) p value*
Age at ECP
≥Median 37 (20-70) 0.32 22 (9-53) 0.74
<Median 61 (42-88) 47 (29-76)
Sex
Male 44 (25-76) 0.43 25 (13-47) 0.01
Female 56 (37-84) 67 (42-100)
Stem cell source
BM 54 (37-80) 0.65 47 (28-78) 0.67
PB 33 (13-84) 25 (12-53)
CB 67 (30-100) NA
Sex mismatch
Female > male 57 (30-100) 0.52 22 (9-53) 0.23
Other 48 (32-71) 53 (34-83)
GVHD grade
II 81 (64-100) 0.0008 NA
III 33 (15-74) NA
IV 0 NA
Donor type
MFD 42 (27-66) 0.11 27 (14-51) 0.14
MUD 75 (50-100) 54 (32-93)
First-line therapy
Steroids 56 (41-77) 0.11 NA
Steroids plus other 0 NA
Visceral aGVHD
Yes 33 (57-100) 0.03 NA
No 77 (18-61) NA
cGVHD onset
De novo NA 50 (28-88) 0.30
Quiescent NA 28 (12-65)
Progressive NA 27 (10-71)
Seattle criteria
Limited NA 67 (45-91) 0.003
Extensive NA 20 (9-44)
NIH criteria
Mild NA 57 (36-90) 0.07
Moderate NA 28 (13-58)
Severe NA 0
CIBMTR criteria
RG1 NA 50 (27-94) 0.85
RG2 NA 32 (18-57)
≥RG3 NA 0
TNCs/kg
≥Median 46 (26-83) 0.68 37 (20-70) 0.53
<Median 43 (23-78) 40 (21-74)
Lymphocytes/kg
≥Median 43 (23-78) 0.95 50 (31-82) 0.60
<Median 46 (26-83) 27 (11-62)
WBCs before ECP
≥Median 56 (37-84) 0.94 47 (29-76) 0.21
<Median 44 (25-76) 22 (9-53)
Lymphocytes before ECP
≥Median 57 (36-90) 0.72 42 (25-71) 0.57
<Median 44 (25-76) 28 (13-58)
Monocytes before ECP
≥Median 45 (28-73) 0.43 41 (23-72) 0.45
<Median 57 (36-90) 37 (20-71)
PLTs before ECP
≥Median 53 (33-86) 0.50 37 (20-66) 0.70
<Median 47 (29-76) 33 (17-64)
* The p value for aGVHD-free survival and cGVHD-free survival was calculated according to the Gray test.35
BM = bone marrow; CB = cord blood; female > male = female donor for a male recipient; PB = peripheral blood.
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(DC) differentiation pathway, within a single day, as deter-
mined by enhanced expression of over 1000 genes, inde-
pendent of disease state, supporting the concept that, in
the future, the ECP might represent a source of DC.44
In our study, aGVHD patients had an ORR of 65%,
which is comparable with data in other reports in the
literature.45-47 In particular, we showed that the ECP
response was associated with aGVHD severity and with
the first line of aGVHD-therapy. A trend for poorer aGVHD
response was observed when the visceral organs were
involved (p = 0.07). In contrast to the study by Perotti and
colleagues,45 which showed no association between the
grade of aGVHD and the response, in our series, we found
a high response rate in aGVHD Grades II and III but not in
aGVHD Grade IV, confirming a previous experience of
high activity of ECP on early aGVHD.48 These data were
then confirmed as a long-term benefit of ECP on early
GVHD. Moreover, when we analyzed the TRM incidence,
the ECP responders had not only a significantly lower
TRM, but also no significant difference in relapse was
observed, suggesting the presence of an immunosuppres-
sive effect without the abrogation or reduction of the
anti-leukemic activity (GVL). Finally, when the OS was
analyzed among responders and nonresponders, a signifi-
cant difference was observed, gaining evidence that a pos-
sible long-term GVHD remission might also be obtained
for patients with steroid-refractory or -dependent aGVHD.
Since very few studies have been addressed to estab-
lish hematologic variables predicting responses to ECP in
either aGVHD or cGVHD, one of the aims of this study was
to test whether the collected TNCs or lymphocytes in the
first month from ECP start, together with the pre-ECP
hematologic values, were able to discriminate patients’
responses to ECP. We observed that neither aGVHD
response nor aGVHD-free survival were associated with
cell doses even when the hematologic counts or apheresis
yield were divided into quartiles, confirming literature
reports.45 A possible explanation is given by studies
showing how the cell type (the number of dendritic cells
or the number of regulatory T cells generated) can affect
the GVHD response;25-27,39-44 therefore, it appears evident
that the biologic response is probably the key affecting the
response, something this study indirectly confirms.
The early intervention with ECP, as previously
reported, was statistically associated with a higher prob-
ability of survival in the aGVHD group, but these data
might be biased by the type of aGVHD occurrence, since
visceral aGVHD had 1) a lower probability of ECP
response, 2) a higher mortality rate, and 3) a need for a
quick intervention.
In the cGVHD cohort, the ORR to ECP was signifi-
cantly associated with the stem cell source, the donor
type, the cGVHD extensive form, and the lymphocyte
apheresis yield. However, the lymphocyte apheretic yield
role was not confirmed when we analyzed the cGVHD-
free survival, whereas the univariate and the multivariate
analysis showed how the female sex and the limited form
of the Seattle classification or the mild form according to
the NIH classification were associated with a better prob-
ability of cGVHD-free survival. While the better outcome
of females remains an unsolved issue, the different
cGVHD-free survival indirectly confirms the findings in
the large series reported by the CIBMTR21 and NIH20
studies in which the mortality (nonrelapse mortality and
OS) was strongly related to cGVHD severity. The CIBMTR
and NIH findings were indirectly confirmed by our article
in which we were able to show a higher cGVHD-free sur-
vival for limited or mild cGVHD. Taken together, we
observed that the early-stage Seattle or NIH had a higher
probability of response, higher cGVHD-free survival,
lower TRM, no higher RI, and finally better OS. More
importantly, the intermediate stages (moderate for NIH or
RG2 for CIBMTR) showed very low CRs, thus confirming
how ECP might have great efficacy in the early-stage
cGVHD but not in the intermediate–advanced ones. As for
the aGVHD cohort, the TNCs/kg harvest or the pre-ECP
hematologic values had no role in cGVHD-free survival,
also suggesting how patients with low WBC counts might
benefit from ECP treatment, without waiting for ECP start.
In conclusion, to our knowledge, this is the first study
aimed at ascertaining whether static or dynamic variables
might predict GVHD responses after ECP. Despite lacking
biologic studies, no significant cell dose effect was
observed, even when the patient cohort was divided into
quartiles.
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